Latest Production News

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

Vault Minerals has settled all its gold forward sales contracts for the second half of FY26 six months early, boosting its exposure to rising gold prices and reinforcing its shareholder value strategy.

Comms Group Limited reported a steady FY25 with revenue growth and a strong start to FY26, driven by the recent TasmaNet acquisition and expanding global contracts. The company is targeting over $75 million in annualised revenue and aims to boost EBITDA to $9-10 million.

Comms Group reported robust FY25 results driven by domestic expansion, including the strategic acquisition of TasmaNet, and strong international growth in its Global and Wholesale division.

Elixir Energy secures a $16.6 million capital raise led by Omega Oil and Gas, propelling Phase-2 of its strategic plan to unlock reserves in Queensland’s Taroom Trough.

Elixir Energy secures $16.6 million in a capital raise led by Omega Oil and Gas, unlocking Phase-2 of its strategic plan to define reserves in Queensland’s Taroom Trough. This funding accelerates appraisal drilling and production testing, positioning Elixir for a pivotal year ahead.

ABx Group has successfully raised over $6 million through a share placement to fund rapid development of its Deep Leads rare earth project and ALCORE pilot plant in Tasmania.

Pure Foods Tasmania has acquired premium ice cream brand Elato, integrating it with its Cashew Creamery to form a new Ice Cream Division led by Elato’s founder. This move broadens PFT’s product range and leverages existing manufacturing capabilities.

Aguia Resources has appointed Tim Hosking as its new CEO, signaling a strategic push towards phosphate production in Brazil set for early 2026, while addressing operational challenges at its Colombian gold project.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Renascor Resources has hit key construction milestones at its Australian Government co-funded Purified Spherical Graphite (PSG) demonstration facility, maintaining schedule for on-site commissioning this quarter. The project aims to establish a competitive, HF-free PSG supply chain outside China.

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.